Ticagrelor, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with
- acute coronary syndromes (ACS) or
- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event
Ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.
Ivosidenib monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least prior line of systemic therapy.
Indicated in the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.
- The treatment of acute, uncomplicated cystitis in women and female adolescents
- Perioperative antibiotic prophylaxis for transrectal prostate biopsy in adult man
Consideration should be given to official guidance on the appropriate use of antibacterial agents
Cetirizine is approved for the following indications:
“In adults, children, and toddlers aged 6 years and above:
For the relief of:
• nasal and ocular symptoms of seasonal and perennial allergic rhinitis,
• symptoms of urticaria.”
For adult patients with type 2 diabetes mellitus:
Sitavia-MET is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately
controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination
of sitagliptin and metformin.
Sitavia-MET is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to
diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a
sulphonylurea.
Sitavia-MET is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma
(PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled
on their maximal tolerated dose of metformin and a PPARγ agonist.
Sitavia-MET is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and
exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide
adequate glycaemic control.
Calcium folinate is indicated:
• To diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”;
• In combination with 5-fluorouracil in cytotoxic therapy.
Calcium folinate is indicated:
• To diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”;
• In combination with 5-fluorouracil in cytotoxic therapy.
